

**EDWARD J. FILIPPONE, MD, FASN**

Clinical Associate Professor of Medicine, Department of Medicine, Division of Nephrology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

**ANJU YADAV, MD**

Assistant Professor, Department of Medicine, Division of Nephrology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA

# Acute kidney injury after hip or knee replacement: Can we lower the risk?

## ABSTRACT

Patients who undergo hip or knee replacement (total joint arthroplasty) face a risk of acute kidney injury that may be higher than previously thought and that increases steeply if they undergo surgical revision to treat prosthetic joint infection. This article assesses the incidence of and risk factors for acute kidney injury after primary total joint arthroplasty or placement of an antibiotic-loaded cement spacer to treat infection, and offers suggestions on how to reduce the risk.

## KEY POINTS

Using current diagnostic criteria, the incidence of acute kidney injury complicating primary total joint arthroplasty may be nearly 10%, and 25% after placement of an antibiotic-loaded cement spacer to treat infection.

In primary total joint arthroplasty, significant risk factors include older age, higher body mass index, chronic kidney disease, comorbidity, anemia, perioperative transfusion, aminoglycoside prophylaxis and treatment, preoperative heart murmur, and renin-angiotensin-aldosterone system blockade.

Acute kidney injury may arise from infection, systemic administration of nephrotoxic antibiotics, and elution of antibiotics from antibiotic-loaded cement.

No randomized controlled trial aimed at reducing acute kidney injury in these settings has been published; however, suggestions for practice modification are made based on the available data.

doi:10.3949/ccjm.86a.18044

**T**OTAL HIP OR KNEE REPLACEMENT (also called total joint arthroplasty) is highly successful at relieving pain and restoring function, but at the risk of acute kidney injury, which is a sudden loss of renal function. Various factors have been associated with this risk, some of which are potentially modifiable, notably, the use of nephrotoxic antibiotics and other drugs.

This review examines the incidence of acute kidney injury using current criteria in total joint arthroplasty of the hip or knee in general, and in the setting of revision surgery for prosthetic joint infection in particular, in which the risk is higher. We identify risk factors for acute kidney injury and propose ways to lower the risk.

## ■ MILLIONS OF PROCEDURES ANNUALLY

Total replacement of the hip<sup>1,2</sup> or knee<sup>3</sup> is being done more and more. Kurtz et al<sup>4</sup> estimate that by the year 2030, we will see approximately 3.5 million primary total knee and 500,000 primary total hip replacements every year. In addition, revision total knee procedures are expected to exceed 250,000 per year, and revision total hip procedures are expected to exceed 90,000 per year.<sup>4</sup>

Chronic infection may complicate up to 2% of these procedures and is associated with significant morbidity, death, and financial costs. Currently, it may be the reason for 25% of total joint arthroplasty revisions,<sup>5</sup> but by the year 2030, it is projected to account for 66% of revision total knee arthroplasties and 48% of revision total hip arthroplasties.<sup>6</sup>

## ACUTE KIDNEY INJURY AFTER ARTHROPLASTY

TABLE 1

### Studies reporting the incidence of acute kidney injury using current diagnostic criteria

Study	No. of patients	Joints involved	Definition of AKI	Incidence of AKI	Risk factors for AKI	Comments
Jafari <sup>7</sup>	17,938	Hip, knee	"I" or "F" of RIFLE criteria	0.55%	BMI, chronic kidney disease, hypertension, COPD, heart failure, heart disease, liver disease	Neglected the most common "R" criteria
Jamsa <sup>8</sup>	20,575	Hip, knee	"I" or "F" of RIFLE	0.28%	Preoperative estimated glomerular filtration rate, ASA score, BMI	Only 5,609 had postoperative serum creatinine measured
Sehgal <sup>9</sup>	659	Knee	AKIN	21.9%	RASB, diabetes	Not independent risk factors
Weingarten <sup>10</sup>	7,463	Hip, knee, shoulder	AKIN	2.2%	BMI, diabetes, PAD, perioperative transfusion, number of antihypertensive medications	93% of AKI cases were only stage 1
Kimme <sup>11</sup>	425	Hip, knee	RIFLE	14.8%	Age, BMI, chronic kidney disease, RASB	
Warth <sup>12</sup>	1,038	Hip, knee	AKIN	5.7%	Age, BMI, diabetes, smoking	AKI in 4.8% of 903 with serum creatinine < 1.2 mg/dL vs 11% if ≥ 1.2
Perregaard <sup>13</sup>	3,410	Hip	KDIGO	2.2%	Chronic kidney disease	AKI in 7% of 374 patients; 11% with chronic kidney disease
Hassan <sup>14</sup>	599	Hip	RIFLE	13.8%	Age, hypertension, general anesthesia, dicloxacillin, low baseline blood pressure	1.7% became permanent dialysis patients
Nowicka <sup>15</sup>	337	Hip, knee	AKIN	6.2%	Chronic kidney disease	AKI in 16.7% with chronic kidney disease vs 4.5% without
Kim <sup>16</sup>	1,309	Knee	KDIGO	4.4%	Age, diabetes, beta-blockers, diuretics, low albumin	Highlights risk of low postoperative albumin
Choi <sup>17</sup>	2,467	Hip	AKIN	4.82%	Postoperative hemoglobin < 10 g/dL	Highlights risk of anemia
Nielson <sup>18</sup>	798	Hip, knee, spinal fusion	KDIGO	4.26%	RASB, BMI, intraoperative hypotension	Highlights risk of RASB
Courtney <sup>19</sup>	1,828	Hip, knee	AKIN	11.3%	Vancomycin, ASA score, reduced glomerular filtration rate	AKI in 13% if vancomycin given
Dubrovskaya <sup>20</sup>	4,177	Hip, knee, spine (1,502)	RIFLE	2.8% (hip and knee)	Diabetes, knee or hip surgery (vs spine)	Not associated with prophylactic gentamicin
Bell <sup>21</sup>	7,666	Hip, knee	KDIGO	7.14%	Gentamicin/flucloxacillin vs cefuroxime prophylaxis	Highlights risk of gentamicin/flucloxacillin
Ross <sup>22</sup>	273	Hip, knee	RIFLE	4%	Gentamicin/flucloxacillin vs cefuroxime prophylaxis	Highlights risk of gentamicin/flucloxacillin
Bailey <sup>23</sup>	238	Hip, knee	RIFLE	5.7%	Gentamicin/flucloxacillin vs cefuroxime prophylaxis	Highlights risk of gentamicin/flucloxacillin
Challagundla <sup>24</sup>	198	Hip, knee	RIFLE	23.7%	Male sex, RASB, high-dose gentamicin/flucloxacillin vs cefuroxime prophylaxis	Highlights risk of gentamicin/flucloxacillin; AKI in 52% of 52 receiving high-dose gentamicin/flucloxacillin
Johansson <sup>25</sup>	136	Hip	KDIGO	20%	Gentamicin/dicloxacillin vs dicloxacillin	Highlights risk of gentamicin
Ferguson <sup>26</sup>	413	Hip, knee	RIFLE	8%	Age, volume of postoperative fluid	RASB and gentamicin not significant
Bjerregaard <sup>27</sup>	1,213	Hip, knee	KDIGO	3.5%	Chronic kidney disease, postoperative hypotension	Only considered the 1,213 patients with prolonged length of stay or 30-day readmission
Friedman <sup>28</sup>	345	Hip, knee	KDIGO	6.3%	Preoperative murmurs, age	Odds ratio 7.73 ( $P < .001$ ) for AKI if preoperative murmur

AKI = acute kidney injury; AKIN = Acute Kidney Injury Network; ASA = American Society of Anesthesiologists; BMI = body mass index; COPD = chronic obstructive pulmonary disease; KDIGO = Kidney Disease Improving Global Outcomes; PAD = peripheral artery disease; RASB = renin-angiotensin system blockade (angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker); RIFLE = risk, injury, failure, loss, end-stage kidney disease

TABLE 2

Current criteria for diagnosing and staging acute kidney injury

Criteria	Stage	Creatinine-based criteria <sup>a</sup>	Urine output-based criteria <sup>a</sup>
<b>RIFLE criteria</b>	R	Rise of serum creatinine of $\geq 50\%$ within 7 days or decrease in GFR of 25%	< 0.5 mL/kg/hour for 6 consecutive hours
	I	Rise of serum creatinine of > 100% or GFR decrease by 50%	< 0.5 mL/kg/hour for 12 consecutive hours
	F	Rise of serum creatinine of > 200% or GFR decrease by 75% or renal replacement therapy	< 0.3 mL/kg/hour for 24 hours or anuria for 12 hours
	L	Complete loss of function for more than 4 weeks	
	E	Complete loss of renal function > 3 months	
<b>AKIN criteria</b>	1	Rise of serum creatinine of $\geq 50\%$ or increase of $\geq 0.3$ mg/dL in < 48 hours	< 0.5 mL/kg/hour for 6 consecutive hours
	2	Rise of serum creatinine of > 100%	< 0.5 mL/kg/hour for 12 consecutive hours
	3	Rise of serum creatinine of > 200% or renal replacement therapy	< 0.3 mL/kg/hour for 24 hours or anuria for 12 hours
<b>KDIGO criteria</b>	1	1.5–1.9 $\times$ baseline within 7 days or 0.3 mg/dL increase within 48 hours	< 0.5 mL/kg/hour for 6–12 hours
	2	2.0–2.9 $\times$ baseline	< 0.5 mL/kg/hour for $\geq 12$ hours
	3	3 $\times$ baseline or increase to > 400 $\mu$ mol/L or renal replacement therapy	< 0.3 mL/kg/hour for $\geq 24$ hours or anuria for $\geq 12$ hours

<sup>a</sup> Satisfaction of either creatinine-based criteria or urine output-based criteria is sufficient for diagnosis and staging. Both are not required.

AKIN = Acute Kidney Injury Network<sup>33</sup>; GFR = glomerular filtration rate; KDIGO = Kidney Disease Improving Global Outcomes<sup>34</sup>; RIFLE = risk, injury, failure, loss, end-stage renal disease<sup>32</sup>

**PRIMARY TOTAL JOINT ARTHROPLASTY AND ACUTE KIDNEY INJURY**

We searched Ovid MEDLINE for articles on acute kidney injury and either arthroplasty or antibiotic-loaded cement spacers. We found 22 studies, with a total of 72,850 patients, that assessed the incidence of acute kidney injury after primary or revision total joint arthroplasty of the hip or knee, or both, using current criteria<sup>7–28</sup> (Table 1), and 3 additional studies that used discharge diagnosis coding.<sup>29–31</sup>

**Study designs, findings varied widely**

The incidence of acute kidney injury varied markedly among the studies of primary total joint arthroplasty or revision for aseptic reasons. Numerous factors explain this heterogeneity.

Designs ranged from single-center studies with relatively small numbers of patients to large regional and national samples based on administrative data.

The definition of acute kidney injury also varied, although many used current criteria, specifically the RIFLE (risk, injury, failure, loss, end-stage renal disease),<sup>32</sup> AKIN (Acute Kidney Injury Network),<sup>33</sup> and KDIGO (Kidney Disease Improving Global Outcomes)<sup>34</sup> creatinine criteria (Table 2). Some studies considered only higher stages of acute kidney injury (equivalent to KDIGO stage 2 or 3), ignoring the most common stage, ie, stage 1. No study considered urine output criteria.

Almost all of the studies were retrospective. We are not aware of any randomized controlled trials.

### Discharge diagnosis may miss many cases

Several studies based the diagnosis of acute kidney injury on International Classification of Diseases, Ninth Revision (ICD-9) coding from hospital discharge summaries.

**Nadkarni et al**,<sup>29</sup> in the largest study published to date, used the nationwide inpatient sample database of more than 7 million total joint arthroplasties and found an incidence of acute kidney injury based on ICD-9 coding of 1.3% over the years 2002 to 2012, although this increased to 1.8% to 1.9% from 2010 to 2012.

**Lopez-de-Andres et al**,<sup>30</sup> in a similar study using the Spanish national hospital discharge database, evaluated 20,188 patients who underwent revision total hip or knee arthroplasty and found an overall incidence of acute kidney injury of 0.94%, also using ICD-9 coding.

**Gharaibeh et al**<sup>31</sup> used similar methods to diagnose acute kidney injury in a single-center study of 8,949 patients and found an incidence of 1.1%.

Although these 3 studies suggest that the incidence of acute kidney injury is relatively low, Grams et al<sup>35</sup> found the sensitivity of ICD-9 coding from hospital records for the diagnosis of acute kidney injury to be only 11.7% compared with KDIGO serum creatinine and urine output criteria. This suggests that the true incidence in these studies may be many times higher, possibly near 10%.

### Do all stages of kidney injury count?

**Jafari et al**,<sup>7</sup> in a large series from a single medical center, used only the “I” (injury) and “F” (failure) levels of the RIFLE criteria (corresponding to stages 2 and 3 of the KDIGO criteria) and found an incidence of 0.55% in more than 17,000 total joint arthroplasties.

**Jamsa et al**<sup>8</sup> used the same criteria for acute kidney injury (only “I” and “F”) and found 58 cases in 5,609 patients in whom postoperative serum creatinine was measured, for an incidence of 1%; the remaining 14,966 patients in their cohort did not have serum creatinine measured, and it was assumed they did not have acute kidney injury. Neither of these studies included the most common “R” (risk) stage of acute kidney injury.

**Parr et al**<sup>36</sup> recently studied a nationwide sample of 657,840 hospitalized veterans and found that of 90,614 who developed acute

kidney injury based on KDIGO creatinine criteria, 84% reached only stage R. This suggests that if all stages were considered, the true incidence of acute kidney injury would have been higher—possibly 4% in the Jafari series and possibly 7% in the Jamsa series.

### Smaller studies had higher rates

Smaller, single-center series reported much higher incidences of acute kidney injury.

**Kimmel et al**<sup>11</sup> found an incidence of 14.8% in 425 total joint arthroplasties using RIFLE creatinine criteria.

**Johansson et al**<sup>25</sup> found an incidence of 19.9% in 136 total joint arthroplasties using KDIGO creatinine criteria.

**Sehgal et al**<sup>9</sup> found an incidence of 21.9% in 659 total joint arthroplasties using AKIN creatinine criteria.

**Challagundla et al**<sup>24</sup> found an incidence of 23.7% in 198 procedures using RIFLE creatinine criteria.

**Weingarten et al**,<sup>10</sup> in a single-center series of 7,463 total joint arthroplasties, found an incidence of acute kidney injury of only 2.2% using AKIN criteria, although 12% of the patients with acute kidney injury did not return to their baseline serum creatinine levels by 3 months.

### Our estimate: Nearly 10%

In total, in the 20 studies in **Table 1** that included all stages of acute kidney injury, there were 1,909 cases of acute kidney injury in 34,337 patients, for an incidence of 5.6%. Considering that all studies but one were retrospective and none considered urine output criteria for acute kidney injury, we believe that using current KDIGO criteria, the true incidence of acute kidney injury complicating primary lower-extremity total joint arthroplasties is really closer to 10%.

## RISK FACTORS FOR ACUTE KIDNEY INJURY

Various factors have been associated with development of acute kidney injury by multivariate analysis in these studies. Some are modifiable, while others are not, at least in the short term.

### Nonmodifiable risk factors

**Older age** is often significant in studies assessing primary total joint arthroplasty or revision

Acute kidney injury may complicate up to 10% of primary total knee or hip replacements

total joint arthroplasty not specifically for infection.<sup>11,12,16,17,26,28</sup>

**Obesity** is also a major factor in the development of acute kidney injury,<sup>7,10–12,17,18</sup> and, along with age, is a major factor contributing to the need for joint replacement in the first place.

**Male sex** may increase risk.<sup>29</sup>

**Diabetes mellitus** was identified as a risk factor in several studies,<sup>10,12,17,20</sup> and **hypertension** in a few.<sup>7,10,24</sup>

**Other comorbidities and factors** such as cardiovascular disease,<sup>7,10</sup> liver disease,<sup>7</sup> pulmonary disease,<sup>7</sup> high American Society of Anesthesiology score,<sup>8,19</sup> and benign heart murmurs preoperatively by routine physical examination have also been linked to acute kidney injury after joint arthroplasty.<sup>28</sup>

### Chronic kidney disease as a risk factor

Chronic kidney disease at baseline was associated with acute kidney injury in several of these series.<sup>7,11–13,15,19,29</sup>

**Warth et al**<sup>12</sup> studied 1,038 patients and found an incidence of acute kidney injury of 11% in the 135 with chronic kidney disease (defined as serum creatinine > 1.2 mg/dL) and who received acetaminophen or narcotics for pain control, compared with 4.8% in the remaining 903 patients without chronic kidney disease, who received ketorolac or celecoxib.

**Perregaard et al**<sup>13</sup> studied 3,410 patients who underwent total hip arthroplasty and found an incidence of acute kidney injury (per KDIGO creatinine criteria) of 2.2% overall, but 7% in the 134 patients with chronic kidney disease based on KDIGO creatinine criteria.

**Nowicka et al**<sup>15</sup> found an incidence of acute kidney injury of 16.7% in the 48 patients with chronic kidney disease (defined as a glomerular filtration rate estimated by the Cockcroft-Gault formula of less than 60 mL/min/1.73 m<sup>2</sup>), compared with 4.5% in the remaining 289.

### Modifiable risk factors

Modifiable risk factors that should be considered in high-risk cases include anemia, perioperative blood transfusion, perioperative use of renin-angiotensin-aldosterone system inhibitors such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), particular antibiotics used

for prophylaxis, and nonsteroidal anti-inflammatory drugs used postoperatively.

### Anemia and blood transfusion

Preoperative anemia has been associated with postoperative acute kidney injury in various surgical settings such as cardiac surgery.<sup>37,38</sup> Perioperative red blood cell transfusions have also been associated with acute kidney injury in cardiac surgery; similar results may apply to total joint arthroplasty.

**Choi et al**,<sup>17</sup> in 2,467 patients undergoing hip replacement, found a significant risk for acute kidney injury if postoperative hemoglobin was consistently below 10 g/dL compared with consistently above this level, with an inverse probability-of-treatment weighted odds ratio of 1.817 ( $P = .011$ ).

Others have found a significant association of perioperative blood transfusion with acute kidney injury in total joint arthroplasty.<sup>10,29</sup>

**Nadkarni et al**,<sup>29</sup> for example, used the nationwide inpatient sample database and found by multivariate analysis that perioperative blood transfusion was strongly associated with acute kidney injury, with an adjusted odds ratio of 2.28 (95% confidence interval [CI] 2.15–2.42,  $P < .0001$ ).

**Comment.** A higher incidence of acute kidney injury may represent confounding by indication bias, as sicker patients or complicated surgeries may require transfusion, and this risk may not be completely accounted for by multivariate analysis. It is also possible, however, that transfusions per se may contribute to acute kidney injury. Possible direct or indirect mechanisms mediating acute kidney injury include hemolytic reactions, circulatory overload, acute lung injury, and immunomodulatory effects.<sup>39</sup>

Preoperative transfusion in anemic patients undergoing cardiac surgery may also reduce the incidence of postoperative acute kidney injury both by correcting the anemia and by limiting the need for perioperative transfusions.<sup>40</sup> It remains to be determined whether elective preoperative transfusion to correct anemia would reduce postoperative development of acute kidney injury in total joint arthroplasty. As an aside, perioperative transfusion has also been linked to development of periprosthetic joint infection.<sup>41</sup>

**20 studies,  
34,337 patients,  
1,909 cases  
(5.6% incidence)  
of acute kidney  
injury**

### Renin-angiotensin-aldosterone system inhibitors

Several studies found perioperative use of renin-angiotensin-aldosterone system inhibitors to be a risk factor for acute kidney injury.

**Kimmel et al<sup>11</sup>** reported adjusted odds ratios of 2.70 (95% CI 1.12–6.48) for ACE inhibitor use and 2.64 (95% CI 1.18–5.93) for ARB use in a study of 425 primary total joint arthroplasties.

**Challagundla et al<sup>24</sup>** found an odds ratio of 3.07 (95% CI 1.40–6.74) with ACE inhibitor or ARB use by multivariate analysis in 198 total joint arthroplasties.

**Nielson et al<sup>18</sup>** studied 798 patients who underwent total joint arthroplasty and found that preoperative use of renin-angiotensin system inhibitors was associated with a significantly higher rate of postoperative acute kidney injury (8.3% vs 1.7% without inhibition), which was statistically significant by multivariate analysis (odds ratio 2.6, 95% CI 1.04–6.51).

**We recommend** holding renin-angiotensin-aldosterone system inhibitors 7 days before surgery through the postoperative period in high-risk cases.

### Aminoglycoside use as a risk factor

Prophylactic administration of systemic antibiotics is the standard of care. In a systematic review of 26 studies and meta-analysis of 7 studies (3,065 patients), prophylactic antibiotics reduced the relative risk of wound infection by 81% with an absolute risk reduction of 8%.<sup>42</sup>

A modifiable risk factor for acute kidney injury is the specific antibiotic used for prophylaxis. Multiple studies assessed the risk of acute kidney injury comparing regimens containing an aminoglycoside (typically gentamicin) with regimens lacking these agents.<sup>20–26</sup> In general, these studies found a significantly higher risk of acute kidney injury when gentamicin was used.

**Challagundla et al<sup>24</sup>** found an incidence of acute kidney injury of 52% using RIFLE creatinine criteria in 52 patients receiving 8 g total of flucloxacillin plus 160 mg of gentamicin (120 mg if they weighed less than 60 kg) compared with 8% in 48 patients given cefuroxime (3 g total) and 14% in an additional

52 patients also given cefuroxime.

**Johansson et al<sup>25</sup>** found an incidence of KDIGO creatinine-based acute kidney injury of 13% in 70 patients given dicloxacillin alone prophylactically compared with 27% given dicloxacillin and gentamicin, with a relative risk of 3.

**Bell et al,<sup>21</sup>** in a large registry-based analysis from Scotland involving 7,666 elective orthopedic procedures, found that use of flucloxacillin 2 g plus a single dose of gentamicin 4 mg/kg was significantly associated with a 94% higher risk of acute kidney injury (KDIGO creatinine criteria) compared with a cefuroxime-based regimen, with absolute rates increasing from 6.2% to 10.8%.

**Dubrovskaya et al<sup>20</sup>** and **Ferguson et al,<sup>26</sup>** in contrast, found no increased risk with addition of gentamicin.

**We recommend** avoiding aminoglycosides for prophylaxis in primary lower-extremity total joint arthroplasty in patients at higher risk unless required for specific microbiologic reasons.

### Vancomycin may also increase risk

**Courtney et al<sup>19</sup>** assessed the risk of adding vancomycin to cefazolin for routine prophylaxis in a retrospective series of 1,828 total hip or knee arthroplasties and found a significantly higher rate of acute kidney injury, using AKIN criteria (13% vs 8%, odds ratio by multivariate analysis 1.82,  $P = .002$ ).<sup>19</sup>

Other agents shown to be effective in treating periprosthetic joint infections or complicated skin and soft-tissue infections with resistant organisms include daptomycin<sup>43</sup> and linezolid.<sup>44</sup> These nonnephrotoxic alternatives to vancomycin may be a consideration if prophylaxis for methicillin-resistant *Staphylococcus aureus* is deemed necessary in patients at risk for acute kidney injury.

### PROSTHETIC JOINT INFECTIONS AND ANTIBIOTIC-LOADED CEMENT

Deep infection may complicate nearly 1% of total hip<sup>45</sup> and 2% of total knee arthroplasties.<sup>46</sup> Kurtz et al<sup>46</sup> have projected that by 2030, infection will be the cause of two-thirds of the estimated 268,000 revision total knee arthroplasties and about half of the estimated 96,700 revision total hip arthroplasties.

**Think about modifying risk factors in patients at high risk**

The most common method of treating a chronically infected replacement joint is a 2-stage procedure.<sup>5</sup> First, the prosthesis is removed, all infected bone and soft tissue is debrided, and an antibiotic-loaded cement spacer is implanted. Systemic antibiotics are given concurrently, typically for about 6 weeks. After the infection is brought under control, perhaps 2 to 3 months later, the spacer is removed and a new joint is implanted with antibiotic-loaded cement. A 1-stage procedure may be an option in selected cases and would obviate the need for an antibiotic-loaded cement spacer.<sup>47,48</sup>

Of obvious relevance to development of acute kidney injury is the choice and amount of antibiotics embedded in the cement used for spacers and in implantation. Very high antibiotic levels are achieved within the joint space, usually with little systemic absorption, although significant systemic exposure has been documented in some cases.

The polymethylmethacrylate cement used for these purposes comes in 40-g bags. Multiple bags are typically required per joint, perhaps 2 to 4.<sup>49</sup>

The rate of elution of antibiotics is determined by several factors, including surface area, porosity, and the number of antibiotics. In general, elution is greatest early on, with exponential decline lasting perhaps 1 week, followed by slow, sustained release over weeks to months.<sup>50</sup> However, several *in vitro* studies have indicated that only about 5%<sup>50,51</sup> of the total antibiotic actually elutes over time.

Initially, multiple antibiotic-laden cement beads were used to fill the joint space, but this significantly limited function and mobility.<sup>52</sup> Now, cement spacers are used, and they can be nonarticulating or articulating for maximal joint mobility.<sup>53</sup> Although much greater antibiotic elution occurs from beads due to their high surface area-to-volume ratio, spacers still provide an adequate dose.

**■ ANTIBIOTIC-LOADED CEMENT: DOSAGE AND ELUTION CHARACTERISTICS**

Antibiotic-loaded cement can be either low-dose or high-dose.

**Low-dose cement**

Low-dose cement typically consists of 0.5 to

1.0 g of antibiotic per 40-g bag of cement, usually an aminoglycoside (gentamicin or tobramycin) or vancomycin, and can be purchased premixed by the manufacturer. Such cement is only used prophylactically with primary total joint arthroplasty or revision for aseptic reasons, a practice common in Europe but less so in the United States. Some American authors propose antibiotic-loaded cement prophylaxis for patients at high risk, eg, those with immunosuppression, inflammatory cause of arthritis, or diabetes.<sup>54</sup>

Vrabec et al,<sup>55</sup> in a study of low-dose tobramycin-loaded cement used for primary total knee arthroplasty, found a peak median intra-articular tobramycin concentration of 32 mg/L at 6 hours, declining to 6 mg/L at 48 hours with all serum levels 0.3 mg/L or less (unmeasurable) at similar time points.

Sterling et al,<sup>56</sup> studying primary total hip arthroplasties with low-dose tobramycin-loaded cement, found mean levels in drainage fluid of 103 mg/L at 6 hours, declining to 15 mg/L at 48 hours. Serum levels peaked at 0.94 mg/L at 3 hours, declining to 0.2 mg/L by 48 hours.

Although most of the antibiotic elution occurs early (within the first week), antibiotic can be found in joint aspirates up to 20 years later.<sup>57</sup> We are unaware of any well-documented cases of acute kidney injury ascribable to low-dose antibiotic-loaded cement used prophylactically. One case report making this assertion did not determine serum levels of aminoglycoside.<sup>58</sup>

**High-dose cement**

High-dose antibiotic-loaded cement typically contains about 4 to 8 g of antibiotic per 40-g bag of cement and is used in the treatment of prosthetic joint infection to form the spacers. The antibiotic must be mixed into the cement powder by the surgeon in the operating room.

There is no standard combination or dosage. The choice of antibiotic can be tailored to the infecting organism if known. Otherwise, gram-positive organisms are most common, and vancomycin and aminoglycosides are often used together. This particular combination will enhance the elution of both antibiotics when studied *in vitro*, a process termed “passive opportunism.”<sup>59</sup> Other anti-

**The most common method of treating a chronically infected replacement joint is a 2-stage procedure**

TABLE 3

**Acute kidney injury in patients with antibiotic-loaded cement spacers for treatment of prosthetic joint infection of the hip and knee**

Study <sup>a</sup>	Joints	No. of patients	Antibiotics in spacer <sup>b</sup>	Definition of AKI	Incidence of AKI	Risk factors for AKI	Comments
Jung <sup>68</sup>	Hip	82	Vancomycin 4 g Gentamicin 1 g/80 g	Undefined	6%	Undefined	2 required dialysis
Hsieh <sup>52</sup>	Hip	99	Vancomycin, gentamicin, aztreonam, tobramycin	Rise of serum creatinine $\geq 0.5$ mg/dL or $\geq 50\%$	5%	Undefined	AKI attributed to systemic antibiotics
Menge <sup>69</sup>	Knee	84	Vancomycin, tobramycin (variable doses)	Rise in serum creatinine $\geq 50\%$ (to $> 1.4$ mg/dL) within 90 days	17%	Related to dose of vancomycin ( $> 4$ g) and tobramycin ( $> 4.8$ g) in spacer	Not associated with systemic vancomycin or tobramycin
Gooding <sup>70</sup>	Knee	115	Vancomycin 1.5 g Tobramycin 3.6 g	Undefined	2%	Undefined	
Springer <sup>71</sup>	Knee	36	Vancomycin mean 10.5 g/spacer, Gentamicin mean 12.5 g/spacer	Rise in serum creatinine	3%	Undefined	
Noto <sup>72</sup>	Hip, knee	46	Tobramycin mean 8.2 g/spacer Vancomycin mean 7.6 g/spacer	$> 50\%$ rise in serum creatinine	22%	All patients tested had detectable tobramycin levels (mean 3.3, range 0.1–19.8 mg/L)	No systemic tobramycin
Aeng <sup>73</sup>	Hip, knee	50	Tobramycin mean 3.6 g/40 g Vancomycin mean 1.5 g/40 g	AKIN	20%	Cement premixed with gentamicin, intraoperative transfusion, NSAIDs	No difference in antibiotic dose in cement with AKI
Geller <sup>74</sup>	Hip, knee	247	Vancomycin with tobramycin or gentamicin: Vancomycin mean 5.3/40 g Tobramycin mean 5.2/40 g Gentamicin mean 1.3 g/40 g	KDIGO	26%	BMI, lower preoperative hemoglobin, decrease in hemoglobin, comorbidity	Not related to dose of vancomycin in spacer
Reed <sup>75</sup>	Hip, knee, shoulder, digits	313 (306 non-dialysis)	Vancomycin median 1 g and/or tobramycin (median 1.2 g) in all but 1	RIFLE	9% (26/306)	ACEI exposure within 7 days, piperacillin-tazobactam within 7 days	109 hip or knee AKI not related to dose in spacer
Yadav <sup>81</sup>	Hip, knee	197	Vancomycin and tobramycin	RIFLE	29%	Age, Charlson comorbidity index score, modest renal impairment	

<sup>a</sup>Two studies (Chohfi et al<sup>50</sup> and Forsythe et al<sup>77</sup>) used antibiotic-loaded cement in primary arthroplasty, not in a spacer for treatment of infected joints.

<sup>b</sup>Dosages expressed as grams per 40-g bag of cement, grams per spacer, grams per 80 g of cement, or not specified.

ACEI = angiotensin-converting enzyme inhibitor; AKI = acute kidney injury; AKIN = Acute Kidney Injury Network; BMI = body mass index; KDIGO = Kidney Disease Improving Global Outcomes; NSAID = nonsteroidal anti-inflammatory drug; RIFLE = risk, injury, failure, loss, end-stage renal disease

biotics in use include aztreonam, piperacillin, teicoplanin, fluoroquinolones, cephalosporins, and daptomycin, among others.

About 8 g of antibiotic total per 40-g bag is the maximum to allow easy molding.<sup>52</sup> As an example, this may include 4 g of vancomycin and 3.6 g of tobramycin per 40 g. Given that 3 to 4 such bags are often used per joint, there is significant risk of systemic exposure.

Kalil et al<sup>60</sup> studied 8 patients who received

high-dose tobramycin-loaded cement to treat periprosthetic joint infections of the hip or knee and found that 7 had detectable serum levels (mean 0.84 mg/L, highest 2.0 mg/L), including 1 with a level of 0.9 mg/L on day 38; 4 of these 8 developed acute kidney injury by AKIN criteria, although other risk factors for acute kidney injury existed. Nearly all had concomitant vancomycin (3 to 8 g) added to the cement as well.

Hsieh et al<sup>61</sup> studied 46 patients with infected total hip arthroplasties treated with high-dose antibiotic-loaded cement spacers (vancomycin 4 g and aztreonam 4 g per 40-g bag) and found vancomycin levels in joint drainage higher than 1,500 mg/L on day 1, decreasing to 571 mg/L on day 7; serum levels were low (range 0.1–1.6 mg/L at 24 hours), falling to undetectable by 72 hours.

■ **ANTIBIOTIC-LOADED CEMENT SPACERS AND ACUTE KIDNEY INJURY**

Case reports have associated high-dose antibiotic-loaded cement spacers with acute kidney injury.

Curtis et al<sup>62</sup> described an 85-year-old patient with stage 3 chronic kidney disease who was treated for an infected total knee arthroplasty with an antibiotic-loaded cement spacer (containing 3.6 g of tobramycin and 3 g of cefazolin per 40-g bag, 3 bags total) and developed stage 3 acute kidney injury. After 16 days and 3 hemodialysis sessions, the patient’s serum tobramycin level was still 2 mg/L despite receiving no systemic tobramycin.

Wu et al<sup>63</sup> reported a case of acute kidney injury that required dialysis after implantation of a tobramycin- and vancomycin-loaded spacer, with persistent serum tobramycin levels despite repeated hemodialysis sessions until the spacer was removed.

Chalmers et al<sup>64</sup> described 2 patients with acute kidney injury and persistently elevated serum tobramycin levels (3.9 mg/L on day 39 in 1 patient and 2.0 mg/L on day 24 in the other patient) despite no systemic administration.

In these and other case reports,<sup>65–67</sup> dialysis and spacer explantation were usually required.

**Comment.** It is intuitive that acute kidney injury would more likely complicate revision total joint arthroplasties for infection than for primary total joint arthroplasties or revisions for aseptic reasons, given the systemic effects of infection and exposure to nephrotoxic or allergenic antibiotics. And the available data suggest that the risk of acute kidney injury is higher with revision for prosthetic joint infection than with revision for aseptic reasons. However, many of the studies were retrospective, relatively small, single-center series and

used different definitions of acute kidney injury.

We are aware of 17 studies specifically addressing acute kidney injury or postoperative complications in general that may have included acute kidney injury.<sup>50,52,61,68–81</sup> Ten of these studies found at least 1 case of acute kidney injury (Table 3). Of note, 7 studies totaling 219 patients reported no cases of acute kidney injury, although acute kidney injury per se was not mentioned and no definition of it was provided.<sup>50,61,76,77,79,80,82</sup>

Luu et al<sup>83</sup> performed a systematic review of studies published between January 1989 and June 2012 reporting systemic complications (including acute kidney injury) of 2-stage revision arthroplasties including placement of an antibiotic-loaded cement spacer for treatment of periprosthetic joint infection. Overall, 10 studies were identified with 544 total patients. Five of these studies, with 409 patients, reported at least 1 case of acute kidney injury for a total of 27 patients, giving an incidence of 6.6% in these studies.<sup>68–71</sup> The remaining 5 studies, totaling 135 patients, did not report any cases of acute kidney injury,<sup>50,61,76–78</sup> although that was not the primary focus of any of those trials.

Most notable from this systematic review, the study of Menge et al<sup>69</sup> retrospectively determined the incidence of acute kidney injury (defined as a 50% rise in serum creatinine to > 1.4 mg/dL within 90 days of surgery) to be 17% in 84 patients with infected total knee arthroplasties treated with antibiotic-loaded cement spacers. A mean of 3.5 bags of cement per spacer were used in the 35 articulating spacers, compared with 2.9 per nonarticulating spacer. These spacers contained vancomycin in 82% (median 4.0 g, range 1–16 g) and tobramycin in 94% (median 4.8 g, range 1–12 g), among others in small percentages. The dose of tobramycin in the spacer considered either as a dichotomous variable (> 4.8 g, OR 5.87) or linearly (OR 1.24 per 1-g increase) was significantly associated with acute kidney injury, although systemic administration of aminoglycosides or vancomycin was not.

Additional single-center series that were published subsequent to this review have generally used more current diagnostic criteria.

Noto et al<sup>72</sup> found that 10 of 46 patients

**Depending on the dose of antibiotics in spacer cement, systemic absorption of nephrotoxic antibiotics can occur**

treated with antibiotic-loaded cement spacers had a greater than 50% rise in serum creatinine (average increase 260%). All spacers contained tobramycin (mean dose 8.2 g), and 9 of 10 also contained vancomycin (mean 7.6 g). All of the 9 patients with acute kidney injury with follow-up data recovered renal function.

Reed et al<sup>75</sup> found 26 cases of acute kidney injury (based on RIFLE creatinine criteria) in 306 patients with antibiotic-loaded cement spacers treating various periprosthetic joint infections (including hips, knees, shoulders, and digits) and compared them with 74 controls who did not develop acute kidney injury. By multivariable analysis, receipt of an ACE inhibitor within 7 days of surgery and receipt of piperacillin-tazobactam within 7 days after surgery were both significantly more common in cases with acute kidney injury than in controls without acute kidney injury.

Aeng et al<sup>73</sup> prospectively studied 50 consecutive patients receiving antibiotic-loaded spacers containing tobramycin (with or without vancomycin) for treatment of infected hip or knee replacements. Using RIFLE creatinine criteria, they found an incidence of acute kidney injury of 20% (10 of 50). Factors significantly associated with acute kidney injury included cement premixed by the manufacturer with gentamicin (0.5 g per 40-g bag) in addition to the tobramycin they added, intraoperative blood transfusions, and postoperative use of nonsteroidal anti-inflammatory drugs.

Geller et al,<sup>74</sup> in a multicenter retrospective study of 247 patients with prosthetic joint infections (156 knees and 91 hips) undergoing antibiotic-loaded cement spacer placement, found an incidence of acute kidney injury of 26% based on KDIGO creatinine criteria. Significant risk factors included higher body mass index, lower preoperative hemoglobin level, drop in hemoglobin after surgery, and comorbidity (hypertension, diabetes, chronic kidney disease, or cardiovascular disease). Most of the spacers contained a combination of vancomycin and either tobramycin (81%) or gentamicin (13%). The spacers contained an average of 5.3 g (range 0.6–18 g) of vancomycin (average 2.65 g per 40-g bag) and an average of 5.2 g (range 0.5–16.4 g) of tobramycin (average 2.6 g per bag).

As in Menge et al,<sup>69</sup> this study illustrates the wide range of antibiotic dosages in use and the lack of standardization. In contrast to the study by Menge et al, however, development of acute kidney injury was not related to the amount of vancomycin or tobramycin contained in the spacers. Eventual clearance of infection (at 1 and 2 years) was significantly related to increasing amounts of vancomycin. Multiple different systemic antibiotics were used, most commonly vancomycin (44%), and systemic vancomycin was not associated with acute kidney injury.

Yadav et al,<sup>81</sup> in a study of 3,129 consecutive revision procedures of the knee or hip, found an incidence of acute kidney injury by RIFLE creatinine criteria of 29% in the 197 patients who received antibiotic-loaded cement spacers for periprosthetic joint infection compared with 3.4% in the 2,848 who underwent revision for aseptic reasons. In 84 patients with prosthetic joint infection having various surgeries not including placement of a spacer, the acute kidney injury rate at some point in their course was an alarmingly high 82%. In the group that received spacers, only age and comorbidity as assessed by Charlson comorbidity index were independently associated with acute kidney injury by multivariate analysis. Surprisingly, modest renal impairment was protective, possibly because physicians of patients with chronic kidney disease were more vigilant and took appropriate measures to prevent acute kidney injury.

Overall, the risk of acute kidney injury appears to be much higher during treatment of prosthetic joint infection with a 2-stage procedure using an antibiotic-loaded cement spacer than after primary total joint arthroplasty or revision for aseptic reasons, and may complicate up to one-third of cases.

### REDUCE RISK DURING TREATMENT OF INFECTED REPLACEMENT JOINTS

Due to lack of appropriate data, how best to mitigate the risk of acute kidney injury is uncertain. In our opinion, however, the following measures should be considered (Table 4).

As in primary total joint arthroplasty in general, higher-risk cases should be identified based on age, body mass index, chronic kidney disease,

**Monitor urine output and serum creatinine for at least 72 hours after surgery**

comorbidities (hypertension, diabetes, established cardiovascular disease), and anemia.

Preoperative transfusion can be considered case by case depending on degree of anemia and associated risk factors.

All renin-angiotensin-aldosterone system inhibitors should be withheld starting 1 week before surgery.

Both nonselective and cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs should be avoided, if possible.

Strict attention should be paid to adequate intraoperative and postoperative fluid resuscitation.

Kidney function should be monitored closely in the early postoperative period, including urine output and daily creatinine for at least 72 hours.

Systemic administration of potentially nephrotoxic antibiotics should be minimized, especially the combination of vancomycin with piperacillin-tazobactam.<sup>84</sup> Daptomycin is a consideration.<sup>43</sup>

If acute kidney injury should develop, serum levels of vancomycin or aminoglycosides should be measured if the spacer contains these antibiotics. The spacer may need to be removed if toxic serum levels persist.

### ■ TAKE-HOME POINTS

Acute kidney injury may complicate up to 10% of primary lower-extremity total joint arthroplasties and up to 25% of periprosthetic joint infections treated with a 2-stage procedure including placement of an antibiotic-loaded cement spacer in the first stage.

Risk factors for acute kidney injury include older age, obesity, chronic kidney disease, and overall comorbidity. Potentially modifiable risk factors include anemia, perioperative transfusions, aminoglycoside prophylaxis, perioperative renin-angiotensin system blockade, and postoperative nonsteroidal anti-inflammatory drugs. These should be mitigated when possible.

In patients with periprosthetic joint infec-

### ■ REFERENCES

1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. *Lancet* 2007; 370(9597):1508–1519. doi:10.1016/S0140-6736(07)60457-7
2. Pivec R, Johnson AJ, Mears SC, Mont MA. Hip arthroplasty. *Lancet*

TABLE 4

### Suggestions for practice modifications<sup>a</sup>

#### Identify higher-risk patients

- Older age<sup>11,12,16,17,26,28,81</sup>
- Higher body mass index<sup>10–12,17,18,74</sup>
- Diabetes mellitus<sup>10,12,17,20</sup>
- Higher comorbidity: cardiovascular disease, hypertension, liver disease, pulmonary disease, higher American Society of Anesthesiologists score<sup>7,8,10,19,24,74,81</sup>
- Chronic kidney disease<sup>7,11–13,15,19,29</sup>
- Benign heart murmurs<sup>28</sup>

#### Consider the following in higher-risk cases of primary total joint arthroplasty or any periprosthetic joint infection

- Hold renin-angiotensin-aldosterone system blockers perioperatively<sup>11,18,24,75</sup>
- Avoid perioperative blood transfusion<sup>10,29,73</sup>
- Correct anemia preoperatively if possible<sup>17,74</sup>
- Avoid aminoglycoside prophylaxis unless needed for periprosthetic joint infection<sup>21–25</sup>
- Avoid perioperative nonsteroidal anti-inflammatory drugs<sup>73</sup>
- Play close attention to postoperative urine output
- Follow serum creatinine daily for at least 48–72 hours

#### Additional modifications in cases of prosthetic joint infection

- Avoid systemic aminoglycosides unless needed for microbiologic reasons
- Avoid the combination of systemic vancomycin with piperacillin-tazobactam<sup>75,84</sup>
- Determine the amount of antibiotics per 40-g bag of antibiotic-loaded cement and the number of bags used<sup>69</sup>
- Check serum levels of vancomycin and aminoglycosides if contained in the cement

<sup>a</sup>Based on the authors' opinions, given only level III or IV scientific evidence with supporting references.

tion who receive antibiotic-loaded cement spacers, especially patients with additional risk factors for acute kidney injury, strict attention should be paid to the dose of antibiotic in the spacer, with levels checked postoperatively if necessary. Nonnephrotoxic antibiotics should be chosen for systemic administration when possible.

Prospective randomized controlled trials are needed to guide therapy after total joint arthroplasty, and to verify the adverse long-term outcomes of acute kidney injury in this setting. ■

- 2012; 380(9855):1768–1777. doi:10.1016/S0140-6736(12)60607-2
3. Carr AJ, Robertsson O, Graves S, et al. Knee replacement. *Lancet* 2012; 379(9823):1331–1340. doi:10.1016/S0140-6736(11)60752-6
4. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. *J Bone Joint Surg Am* 2007; 89(4):780–785.

## ACUTE KIDNEY INJURY AFTER ARTHROPLASTY

- doi:10.2106/JBJS.F.00222
5. **Kapadia BH, Berg RA, Daley JA, Fritz J, Bhawe A, Mont MA.** Periprosthetic joint infection. *Lancet* 2016; 387(10016):386–394. doi:10.1016/S0140-6736(14)61798-0
  6. **Kurtz SM, Ong KL, Schmier J, et al.** Future clinical and economic impact of revision total hip and knee arthroplasty. *J Bone Joint Surg Am* 2007; 89(suppl 3):144–151. doi:10.2106/JBJS.G.00587
  7. **Jafari SM, Huang R, Joshi A, Parvizi J, Hozack WJ.** Renal impairment following total joint arthroplasty: who is at risk? *J Arthroplasty* 2010; 25(6 suppl):49–53, 53.e1–2. doi:10.1016/j.arth.2010.04.008
  8. **Jamsa P, Jamsen E, Lyytikäinen LP, Kalliovalkama J, Eskelinen A, Oksala N.** Risk factors associated with acute kidney injury in a cohort of 20,575 arthroplasty patients. *Acta Orthop* 2017; 88(4):370–376. doi:10.1080/17453674.2017.1301743
  9. **Sehgal V, Bajwa SJ, Sehgal R, Eagan J, Reddy P, Lesko SM.** Predictors of acute kidney injury in geriatric patients undergoing total knee replacement surgery. *Int J Endocrinol Metab* 2014; 12(3):e16713. doi:10.5812/ijem.16713
  10. **Weingarten TN, Gurrieri C, Jarett PD, et al.** Acute kidney injury following total joint arthroplasty: retrospective analysis. *Can J Anaesth* 2012; 59(12):1111–1118. doi:10.1007/s12630-012-9797-2
  11. **Kimmel LA, Wilson S, Janardan JD, Liew SM, Walker RG.** Incidence of acute kidney injury following total joint arthroplasty: a retrospective review by RIFLE criteria. *Clin Kidney J* 2014; 7(6):546–551. doi:10.1093/ckj/sfu108
  12. **Warth LC, Noiseux NO, Hogue MH, Klaassen AL, Liu SS, Callaghan JJ.** Risk of acute kidney injury after primary and revision total hip arthroplasty and total knee arthroplasty using a multimodal approach to perioperative pain control including ketorolac and celecoxib. *J Arthroplasty* 2016; 31(1):253–255. doi:10.1016/j.arth.2015.08.012
  13. **Perregaard H, Damholt MB, Solgaard S, Petersen MB.** Renal function after elective total hip replacement. *Acta Orthop* 2016; 87(3):235–238. doi:10.3109/17453674.2016.1155130
  14. **Hassan BK, Sahlström A, Dessau RB.** Risk factors for renal dysfunction after total hip joint replacement; a retrospective cohort study. *J Orthop Surg Res* 2015; 10:158. doi:10.1186/s13018-015-0299-0
  15. **Nowicka A, Selvaraj T.** Incidence of acute kidney injury after elective lower limb arthroplasty. *J Clin Anesth* 2016; 34:520–523. doi:10.1016/j.jclinane.2016.06.010
  16. **Kim HJ, Koh WU, Kim SG, et al.** Early postoperative albumin level following total knee arthroplasty is associated with acute kidney injury: a retrospective analysis of 1309 consecutive patients based on kidney disease improving global outcomes criteria. *Medicine (Baltimore)* 2016; 95(31):e4489. doi:10.1097/MD.0000000000004489
  17. **Choi YJ, Kim S, Sim JH, Hahm K.** Postoperative anemia is associated with acute kidney injury in patients undergoing total hip replacement arthroplasty: a retrospective study. *Anesth Analg* 2016; 122(6):1923–1928. doi:10.1213/ANE.0000000000001003
  18. **Nielson E, Hennrikus E, Lehman E, Mets B.** Angiotensin axis blockade, hypotension, and acute kidney injury in elective major orthopedic surgery. *J Hosp Med* 2014; 9(5):283–288. doi:10.1002/jhm.2155
  19. **Courtney PM, Melnic CM, Zimmer Z, Anari J, Lee GC.** Addition of vancomycin to cefazolin prophylaxis is associated with acute kidney injury after primary joint arthroplasty. *Clin Orthop Relat Res* 2015; 473(7):2197–2203. doi:10.1007/s11999-014-4062-3
  20. **Dubrovskaya Y, Tejada R, Bosco J 3rd, et al.** Single high dose gentamicin for perioperative prophylaxis in orthopedic surgery: evaluation of nephrotoxicity. *SAGE Open Med* 2015; 3:2050312115612803. doi:10.1177/2050312115612803
  21. **Bell S, Davey P, Nathwani D, et al.** Risk of AKI with gentamicin as surgical prophylaxis. *J Am Soc Nephrol* 2014; 25(11):2625–2632. doi:10.1681/ASN.2014010035
  22. **Ross AD, Boscainos PJ, Malhas A, Wigderowitz C.** Peri-operative renal morbidity secondary to gentamicin and flucloxacillin chemoprophylaxis for hip and knee arthroplasty. *Scott Med J* 2013; 58(4):209–212. doi:10.1177/0036933013507850
  23. **Bailey O, Torkington MS, Anthony I, Wells J, Blyth M, Jones B.** Antibiotic-related acute kidney injury in patients undergoing elective joint replacement. *Bone Joint J* 2014; 96-B(3):395–398. doi:10.1302/0301-620X.96B3.32745
  24. **Challagundla SR, Knox D, Hawkins A, et al.** Renal impairment after high-dose flucloxacillin and single-dose gentamicin prophylaxis in patients undergoing elective hip and knee replacement. *Nephrol Dial Transplant* 2013; 28(3):612–619. doi:10.1093/ndt/gfs458
  25. **Johansson S, Christensen OM, Thorsmark AH.** A retrospective study of acute kidney injury in hip arthroplasty patients receiving gentamicin and dicloxacillin. *Acta Orthop* 2016; 87(6):589–591. doi:10.1080/17453674.2016.1231008
  26. **Ferguson KB, Winter A, Russo L, et al.** Acute kidney injury following primary hip and knee arthroplasty surgery. *Ann R Coll Surg Eng* 2017; 99(4):307–312. doi:10.1308/rcsann.2016.0324
  27. **Bjerregaard LS, Jorgensen CC, Kehlet H; Lundbeck Foundation Centre for Fast-Track Hip and Knee Replacement Collaborative Group.** Serious renal and urological complications in fast-track primary total hip and knee arthroplasty; a detailed observational cohort study. *Minerva Anestesiol* 2016; 82(7):767–776. PMID:27028450
  28. **Friedman JM, Couso R, Kitchens M, et al.** Benign heart murmurs as a predictor for complications following total joint arthroplasty. *J Orthop* 2017; 14(4):470–474. doi:10.1016/j.jor.2017.07.009
  29. **Nadkarni GN, Patel AA, Ahuja Y, et al.** Incidence, risk factors, and outcome trends of acute kidney injury in elective total hip and knee arthroplasty. *Am J Orthop (Belle Mead NJ)* 2016; 45(1):E12–E19. PMID:26761921
  30. **Lopez-de-Andres A, Hernandez-Barrera V, Martinez-Huedo MA, Villanueva-Martinez M, Jimenez-Trujillo I, Jimenez-Garcia R.** Type 2 diabetes and in-hospital complications after revision of total hip and knee arthroplasty. *PLoS One* 2017; 12(8):e0183796. doi:10.1371/journal.pone.0183796
  31. **Gharaibeh KA, Hamadah AM, Sierra RJ, Leung N, Kremers WK, El-Zoghby ZM.** The rate of acute kidney injury after total hip arthroplasty is low but increases significantly in patients with specific comorbidities. *J Bone Joint Surg Am* 2017; 99(21):1819–1826. doi:10.2106/JBJS.16.01027
  32. **Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup.** Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004; 8(4):R204–R212. doi:10.1186/cc2872
  33. **Mehta RL, Kellum JA, Shah SV, et al; Acute Kidney Injury Network.** Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; 11(2):R31. doi:10.1186/cc5713
  34. **Section 2: AKI Definition.** *Kidney Int Suppl* (2011) 2012; 2(1):19–36. doi:10.1038/kisup.2011.32
  35. **Grams ME, Waikar SS, MacMahon B, Whelton S, Ballew SH, Coresh J.** Performance and limitations of administrative data in the identification of AKI. *Clin J Am Soc Nephrol* 2014; 9(4):682–689. doi:10.2215/CJN.07650713
  36. **Parr SK, Matheny ME, Abdel-Kader K, et al.** Acute kidney injury is a risk factor for subsequent proteinuria. *Kidney Int* 2018; 93(2):460–469. doi:10.1016/j.kint.2017.07.007
  37. **Karkouti K, Wijeyesundera DN, Yau TM, et al.** Acute kidney injury after cardiac surgery: focus on modifiable risk factors. *Circulation* 2009; 119(4):495–502. doi:10.1161/CIRCULATIONAHA.108.786913
  38. **Karkouti K, Grocott HP, Hall R, et al.** Interrelationship of preoperative anemia, intraoperative anemia, and red blood cell transfusion as potentially modifiable risk factors for acute kidney injury in cardiac surgery: a historical multicentre cohort study. *Can J Anaesth* 2015; 62(4):377–384. doi:10.1007/s12630-014-0302-y
  39. **Carson JL, Triulzi DJ, Ness PM.** Indications for and adverse effects of red-cell transfusion. *N Engl J Med* 2017; 377(13):1261–1272. doi:10.1056/NEJMra1612789
  40. **Karkouti K, Wijeyesundera DN, Yau TM, et al.** Advance targeted transfusion in anemic cardiac surgical patients for kidney protection: an unblinded randomized pilot clinical trial. *Anesthesiology* 2012; 116(3):613–621. doi:10.1097/ALN.0b013e3182475e39
  41. **Newman ET, Watters TS, Lewis JS, et al.** Impact of perioperative

- allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty. *J Bone Joint Surg Am* 2014; 96(4):279–284. doi:10.2106/JBJS.L.01041
42. **AlBuhairan B, Hind D, Hutchinson A.** Antibiotic prophylaxis for wound infections in total joint arthroplasty: a systematic review. *J Bone Joint Surg Br* 2008; 90(7):915–919. doi:10.1302/0301-620X.90B7.20498
  43. **Corona Pérez-Cardona PS, Barro Ojeda V, Rodriguez Pardo D, et al.** Clinical experience with daptomycin for the treatment of patients with knee and hip periprosthetic joint infections. *J Antimicrob Chemother* 2012; 67(7):1749–1754. doi:10.1093/jac/dks119
  44. **Itani KM, Biswas P, Reisman A, Bhattacharyya H, Baruch AM.** Clinical efficacy of oral linezolid compared with intravenous vancomycin for the treatment of methicillin-resistant *Staphylococcus aureus*-complicated skin and soft tissue infections: a retrospective, propensity score-matched, case-control analysis. *Clin Ther* 2012; 34(8):1667–1673.e1. doi:10.1016/j.clinthera.2012.06.018
  45. **Dale H, Hallan G, Hallan G, Espehaug B, Havelin LI, Engesaeter LB.** Increasing risk of revision due to deep infection after hip arthroplasty. *Acta Orthop* 2009; 80(6):639–645. doi:10.3109/17453670903506658
  46. **Kurtz SM, Ong KL, Lau E, Bozic KJ, Berry D, Parvizi J.** Prosthetic joint infection risk after TKA in the Medicare population. *Clin Orthop Relat Res* 2010; 468(1):52–56. doi:10.1007/s11999-009-1013-5
  47. **Kunutsor SK, Whitehouse MR, Lenguerrand E, Blom AW, Beswick AD; INFORM Team.** Re-infection outcomes following one- and two-stage surgical revision of infected knee prosthesis: a systematic review and meta-analysis. *PLoS One* 2016; 11(3):e0151537. doi:10.1371/journal.pone.0151537
  48. **Negus JJ, Gifford PB, Haddad FS.** Single-stage revision arthroplasty for infection—an underutilized treatment strategy. *J Arthroplasty* 2017; 32(7):2051–2055. doi:10.1016/j.arth.2017.02.059
  49. **Stevens CM, Tetsworth KD, Calhoun JH, Mader JT.** An articulated antibiotic spacer used for infected total knee arthroplasty: a comparative in vitro elution study of Simplex and Palacos bone cements. *J Orthop Res* 2005; 23(1):27–33. doi:10.1016/j.orthres.2004.03.003
  50. **Chohfi M, Langlais F, Fourastier J, Minet J, Thomazeau H, Cormier M.** Pharmacokinetics, uses, and limitations of vancomycin-loaded bone cement. *Int Orthop* 1998; 22(3):171–177. PMID:9728311
  51. **Amin TJ, Lamping JW, Hendricks KJ, McIff TE.** Increasing the elution of vancomycin from high-dose antibiotic-loaded bone cement: a novel preparation technique. *J Bone Joint Surg Am* 2012; 94(21):1946–1951. doi:10.2106/JBJS.L.00014
  52. **Hsieh PH, Chen LH, Chen CH, Lee MS, Yang WE, Shih CH.** Two-stage revision hip arthroplasty for infection with a custom-made, antibiotic-loaded, cement prosthesis as an interim spacer. *J Trauma* 2004; 56(6):1247–1252. PMID:15211133
  53. **Cui Q, Mihalko WM, Shields JS, Ries M, Saleh KJ.** Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. *J Bone Joint Surg Am* 2007; 89(4):871–882. doi:10.2106/JBJS.E.01070
  54. **Jiranek WA, Hanssen AD, Greenwald AS.** Antibiotic-loaded bone cement for infection prophylaxis in total joint replacement. *J Bone Joint Surg Am* 2006; 88(11):2487–2500. doi:10.2106/JBJS.E.01126
  55. **Vrabec G, Stevenson W, Elguizaoui S, Kirsch M, Pinkowski J.** What is the intraarticular concentration of tobramycin using low-dose tobramycin bone cement in TKA: an in vivo analysis? *Clin Orthop Relat Res* 2016; 474(11):2441–2447. doi:10.1007/s11999-016-5006-x
  56. **Sterling GJ, Crawford S, Potter JH, Koerbin G, Crawford R.** The pharmacokinetics of Simplex-tobramycin bone cement. *J Bone Joint Surg Br* 2003; 85(5):646–649. PMID:12892183
  57. **Fletcher MD, Spencer RF, Langkamer VG, Lovering AM.** Gentamicin concentrations in diagnostic aspirates from 25 patients with hip and knee arthroplasties. *Acta Orthop Scand* 2004; 75(2):173–176. doi:10.1080/00016470412331294425
  58. **Lau BP, Kumar VP.** Acute kidney injury (AKI) with the use of antibiotic-impregnated bone cement in primary total knee arthroplasty. *Ann Acad Med Singapore* 2013; 42(12):692–695. PMID:24463833
  59. **Penner MJ, Masri BA, Duncan CP.** Elution characteristics of vancomycin and tobramycin combined in acrylic bone-cement. *J Arthroplasty* 1996; 11(8):939–944. PMID:8986572
  60. **Kalil GZ, Ernst EJ, Johnson SJ, et al.** Systemic exposure to aminoglycosides following knee and hip arthroplasty with aminoglycoside-loaded bone cement implants. *Ann Pharmacother* 2012; 46(7–8):929–934. doi:10.1345/aph.1R049
  61. **Hsieh PH, Chang YH, Chen SH, Ueng SW, Shih CH.** High concentration and bioactivity of vancomycin and aztreonam eluted from simple cement spacers in two-stage revision of infected hip implants: a study of 46 patients at an average follow-up of 107 days. *J Orthop Res* 2006; 24(8):1615–1621. doi:10.1002/jor.20214
  62. **Curtis JM, Sternhagen V, Batts D.** Acute renal failure after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty. *Pharmacotherapy* 2005; 25(6):876–880. PMID:15927906
  63. **Wu IM, Marin EP, Kashgarian M, Brewster UC.** A case of an acute kidney injury secondary to an implanted aminoglycoside. *Kidney Int* 2009; 75(10):1109–1112. doi:10.1038/ki.2008.386
  64. **Chalmers PN, Frank J, Sporer SM.** Acute postoperative renal failure following insertion of an antibiotic-impregnated cement spacer in revision total joint arthroplasty: two case reports. *JBJS Case Connect* 2012; 2(1):e12. doi:10.2106/JBJS.CC.K.00094
  65. **Patrick BN, Rivey MP, Allington DR.** Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. *Ann Pharmacother* 2006; 40(11):2037–2042. doi:10.1345/aph.1H173
  66. **Dovas S, Liakopoulos V, Papatheodorou L, et al.** Acute renal failure after antibiotic-impregnated bone cement treatment of an infected total knee arthroplasty. *Clin Nephrol* 2008; 69(3):207–212. PMID:18397720
  67. **McGlothlan KR, Gosmanova EO.** A case report of acute interstitial nephritis associated with antibiotic-impregnated orthopedic bone-cement spacer. *Tenn Med* 2012; 105(9):37–40, 42. PMID:23097958
  68. **Jung J, Schmid NV, Kelm J, Schmitt E, Anagnostakos K.** Complications after spacer implantation in the treatment of hip joint infections. *Int J Med Sci* 2009; 6(5):265–273. PMID:19834592
  69. **Menge TJ, Koethe JR, Jenkins CA, et al.** Acute kidney injury after placement of an antibiotic-impregnated cement spacer during revision total knee arthroplasty. *J Arthroplasty* 2012; 27(6):1221–1227. e1–2. doi:10.1016/j.arth.2011.12.005
  70. **Gooding CR, Masri BA, Duncan CP, Greidanus NV, Garbuz DS.** Durable infection control and function with the PROSTALAC spacer in two-stage revision for infected knee arthroplasty. *Clin Orthop Relat Res* 2011; 469(4):985–993. doi:10.1007/s11999-010-1579-y
  71. **Springer BD, Lee GC, Osmon D, Haidukewych GJ, Hanssen AD, Jacofsky DJ.** Systemic safety of high-dose antibiotic-loaded cement spacers after resection of an infected total knee arthroplasty. *Clin Orthop Relat Res* 2004; 427:47–51. PMID:15552135
  72. **Noto MJ, Koethe JR, Miller G, Wright PW.** Detectable serum tobramycin levels in patients with renal dysfunction and recent placement of antibiotic-impregnated cement knee or hip spacers. *Clin Infect Dis* 2014; 58(12):1783–1784. doi:10.1093/cid/ciu159
  73. **Aeng ES, Shalansky KF, Lau TT, et al.** Acute kidney injury with tobramycin-impregnated bone cement spacers in prosthetic joint infections. *Ann Pharmacother* 2015; 49(11):1207–1213. doi:10.1177/1060028015600176
  74. **Geller JA, Cunn G, Herschmiller T, Murtaugh T, Chen A.** Acute kidney injury after first-stage joint revision for infection: Risk factors and the impact of antibiotic dosing. *J Arthroplasty* 2017; 32(10):3120–3125. doi:10.1016/j.arth.2017.04.054
  75. **Reed EE, Johnston J, Severing J, Stevenson KB, Deutscher M.** Nephrotoxicity risk factors and intravenous vancomycin dosing in the immediate postoperative period following antibiotic-impregnated cement spacer placement. *Ann Pharmacother* 2014; 48(8):962–969. doi:10.1177/1060028014535360
  76. **Koo KH, Yang JW, Cho SH, et al.** Impregnation of vancomycin, gentamicin, and cefotaxime in a cement spacer for two-stage cementless reconstruction in infected total hip arthroplasty. *J Arthroplasty* 2001; 16(7):882–892. doi:10.1054/arth.2001.24444

## ACUTE KIDNEY INJURY AFTER ARTHROPLASTY

77. Forsythe ME, Crawford S, Sterling GJ, Whitehouse SL, Crawford R. Safeness of simplex-tobramycin bone cement in patients with renal dysfunction undergoing total hip replacement. *J Orthop Surg (Hong Kong)* 2006; 14(1):38–42. doi:10.1177/230949900601400109
78. Hsieh PH, Huang KC, Tai CL. Liquid gentamicin in bone cement spacers: in vivo antibiotic release and systemic safety in two-stage revision of infected hip arthroplasty. *J Trauma* 2009; 66(3):804–808. doi:10.1097/TA.0b013e31818896cc
79. Hofmann AA, Goldberg T, Tanner AM, Kurtin SM. Treatment of infected total knee arthroplasty using an articulating spacer: 2- to 12-year experience. *Clin Orthop Relat Res* 2005; 430:125–131. PMID:15662313
80. Evans RP. Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method. *Clin Orthop Relat Res* 2004; 427:37–46. PMID:15552134
81. Yadav A, Alijanipour P, Ackerman CT, Karanth S, Hozack WJ, Filippone EJ. Acute kidney injury following failed total hip and knee arthroplasty. *J Arthroplasty* 2018; 33(10):3297–3303. doi:10.1016/j.arth.2018.06.019
82. Hsieh PH, Huang KC, Lee PC, Lee MS. Two-stage revision of infected hip arthroplasty using an antibiotic-loaded spacer: retrospective comparison between short-term and prolonged antibiotic therapy. *J Antimicrob Chemother* 2009; 64(2):392–397. doi:10.1093/jac/dkp177
83. Luu A, Syed F, Raman G, et al. Two-stage arthroplasty for prosthetic joint infection: a systematic review of acute kidney injury, systemic toxicity and infection control. *J Arthroplasty* 2013; 28(9):1490–1498. e1. doi:10.1016/j.arth.2013.02.035
84. Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. *Clin Pharmacol Ther* 2017; 102(3):459–469. doi:10.1002/cpt.726

**ADDRESS:** Edward J. Filippone, MD, FASN, Department of Medicine, Division of Nephrology, Sidney Kimmel Medical College, Thomas Jefferson University, 2228 South Broad Street, Philadelphia, PA 19145; kidneys@comcast.net



# 31st Annual Intensive Review of Internal Medicine

June 10 – 14, 2019

InterContinental Hotel and Bank of America Conference Center | Cleveland, OH

Session on  
test taking strategies  
Access to 100 board  
style questions  
& answers



## HIGHLIGHTS

**Earn ABIM MOC Points**

**Free App for all Attendees!**

Access presentations anytime, anywhere. Take notes, draw, or highlight

**Audience Response System**

Interactive case & MCQ based talks with audience response system

**Meet the Professor Lunches**

Meet subspecialty speakers for one-on-one discussions

**WiFi in Meeting Room**

**Cases from *Cleveland Clinic Journal of Medicine***

Access to useful clinical cases for boards & practice from *Cleveland Clinic Journal of Medicine*



Register Today! [ccfcme.org/GoIRIM](http://ccfcme.org/GoIRIM)

This activity has been approved for AMA PRA Category 1 Credit™.